

Bora Pharmaceuticals Reports Consolidated Revenue of NT\$1.37 Billion in August

保瑞公告 8 月自結合併營收新台幣 13 億 7 仟萬元

Taipei, Taiwan, September 10, 2025 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”) announced that its consolidated revenues for August 2025 reached NT\$1.37 billion, a decrease of 26.6% compared to same period last year. On a year-to-date basis, revenues increased 14.8% compared to the same period last year. Year-to-date revenues grew 14.8%. In U.S. dollar terms, August marked the second slowest month of the year, following March.

台北，台灣，2025 年 9 月 10 日 – 保瑞藥業（以下簡稱「保瑞」，股票代碼：6472）今日公告 8 月自結合併營收為新台幣 13 億 7 仟萬元，較去年同期衰退 26.6%，累計營收年增 14.8%；若以美金計，8 月營收仍較 3 月低谷為高。

During the month, CDMO business has successfully navigated its integration period, posting a 17.5% month-over-month and a 29.7% year-over-year increase, effectively regaining the momentum seen at the beginning of the year. The Company is also seeing increased interest in its US capacity. CDMO revenues grew 59.5% year-to-date. At the Plymouth facility in Minnesota, the property has been divided into 2 phases for sale. The smaller area, suitable for warehousing and packaging lines, has already been sold. Multiple potential buyers are currently evaluating the main production area.

CDMO 業務順利度過整合期，月對月增 17.5%、年對年增 29.7%，已回復年初的動能，1 至 8 月 CDMO 業務年增 59.5%，新客戶詢問美國產能的熱度漸升；其中，明尼蘇達州的 Plymouth 廠區拆分成 2 階段出售，佔地較小可用做倉庫與包裝線的區域已出售，主要生產線區域目前有多組潛在買家評估中。

However, the sell-through of inventory from delisted generic products, discontinued as part of margin optimization efforts, is approaching its end within the pharma sales business. At the same time, August revenue was impacted by the IT infrastructure separation of the Maple Grove CDMO facility from the Upsher-Smith pharma sales company. During the transition, shipment scheduling required adjustments between the two systems. In addition, certain shipments were postponed in response to client requests. As a result, while specialty pharma sales have maintained strong double-digit quarterly growth, this was offset by greater-than-expected seasonality in the generics segment. As of the second week of September, restocking momentum for generics has begun to gradually recover. On a year-to-date basis, sales performance was closely tracked by prior-year levels. The Company continues to focus on growth from specialty pharma and regulatory approvals of its high value generics in the pipeline in the upcoming quarter.

然因優化毛利而下架的學名藥產品庫存銷售趨近尾聲，且 8 月營收因 CDMO 業務 Maple Grove 廠自 Upsher-Smith 營運體系中獨立出來，二個個體系統上線期間出貨必須調整，加上因應客戶需求出貨延

後，儘管特殊專科藥物銷售維持季度雙位數強勁增長，仍不敵學名藥較預期更大的季節性影響，截至 9 月第二周，學名藥拉貨動能逐步復甦，今年全球銷售業務表現與去年相仿，專科藥物的增長以及特殊學名藥第四季的取證仍是後續成長關鍵。

About Bora:

Founded in 2007, Bora Pharmaceuticals ("Bora" or "the Company", 6472.TW) is a leading pharmaceutical services company with a vision and goal of "Contributing to Better Health All Over the World". Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients' quality of life.

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success "certain," Bora sets new standards in the pharmaceutical and CDMO industries.

For more, please visit:

<https://www.bora-corp.com>

<https://www.boracdm.com>

關於保瑞：

保瑞藥業股份有限公司（股票代碼：6472）成立於2007年，是一家領先的製藥服務公司，自成立伊始即秉持「為全世界健康貢獻力量」的願景與目標。保瑞以整合 CDMO（委託開發與製造服務）與藥物開發銷售的「雙引擎」商業模式，協助製藥與生技合作夥伴優化產品開發流程、加速上市時程、擴大供應規模以滿足全球患者的需求。公司亦專注於美國的利基市場及罕見疾病領域，致力於透過拓展銷售通路實力提升患者的生活品質。

透過持續投資人才、生產與銷售及進入生物製劑業務領域，保瑞不斷推動業務升級與永續發展。我們以Making Success More Certain為使命，專注高品質、高效率與可靠性，在製藥及 CDMO 領域樹立新標杆。

請造訪：

企業網站 <https://www.bora-corp.com>

CDMO 網站 <https://www.boracdm.com>

Investor/Media enquiries 新聞聯繫人：

Nadiya Chen, Investor Relations 投資人關係 陳荻雅

+886 2 790-1555 Ext. 9108

Email : Nadiya.Chen@bora-corp.com